Daniel Ricklin

Associate Professor

University of Basel

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Daniel Ricklin is an Associate Professor at Universität Basel, Switzerland. His research areas focus on complement-targeted therapeutics, metabolic glycoengineering, and pharmacokinetics, as evidenced by his recent publications. He is actively exploring innovative methodologies for evaluating complement-regulatory peptide coatings and enhancing drug discovery in the field of complement biology.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (8)

Oliver Schwardt

Senior Scientist & Lecturer

University of Basel

SWITZERLAND

View details

Marko Anderluh

SLOVENIA

View details

Hakon Leffler

Associate Professor - Professor

Lund University

SWEDEN

View details

Christina Lamers

Junior Professor

Leipzig University

GERMANY

View details

John D. Lambris

UNITED STATES

View details

Martin Smieško

Titulaprofessor - Senior Scientist

University of Basel

SWITZERLAND

View details

Said Rabbani

University of Basel

SWITZERLAND

View details

Tihomir Tomašič

SLOVENIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniel Ricklin

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Assay System Based on Metabolic Glycoengineering‐Enabled Click Chemistry for the Efficient Evaluation of Complement‐Regulatory Peptide Coatings on Endothelial Cells

Danicopan: complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria

Erlotinib—A substrate and inhibitor of OATP2B1: pharmacokinetics and CYP3A-mediated metabolism in rSlco2b1−/− and SLCO2B1+/+ rats

Complement‐targeted therapeutics: Are we there yet, or just getting started?

Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery

Complement-regulatory biomaterial coatings: Activity and selectivity profile of the factor H-binding peptide 5C6

Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method

Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors

Compstatins: the dawn of clinical C3-targeted complement inhibition.

Exploring the function of factor XIII free B subunit: Interactions with complement factors and a novel approach to identify potential binding partners.

Front Cover: Selective Monovalent Galectin‐8 Ligands Based on 3‐Lactoylgalactoside (ChemMedChem 3/2022)

Selective Monovalent Galectin‐8 Ligands Based on 3‐Lactoylgalactoside

Complement & disease: out of the shadow into the spotlight.

Tipping the balance: intricate roles of the complement system in disease and therapy

Collaborators (8)

Oliver Schwardt

Marko Anderluh

Hakon Leffler

Christina Lamers

John D. Lambris

Martin Smieško

Said Rabbani

Tihomir Tomašič

Make your next move.